Reply To:
Name - Reply Comment

A locally developed nutraceutical targeting cancer stem cells is expected to generate around two million U.S. dollars in export revenue for Sri Lanka by 2027, according to Prof. Sameera R. Samarakoon of the Institute of Biochemistry, Molecular Biology and Biotechnology, University of Colombo.
The product, launched three years ago, has already gained traction among Sri Lankan consumers, with positive feedback on its effectiveness in improving quality of life.
While emphasizing that it is not a drug, Prof. Samarakoon said the nutraceutical was developed as an alternative approach in the fight against cancer.
“Various methods exist to combat cancer, including surgery, chemotherapy, radiotherapy, targeted therapies, vaccines, and even traditional treatments. Our focus was to develop a product to fight cancer stem cells and support patients in living better lives,” he explained.
“This may not only offer direct anticancer activity but could also be used to reduce side effects commonly associated with cancer treatments. The formula may alleviate therapy-induced toxicity, which makes it a potential adjunct therapy to traditional cancer treatments,” he noted.
Meanwhile, a survey conducted last year by the University of Kelaniya with a sample size of over 300 consumers reported a 93 percent satisfaction rate for the product.
Prof. Samarakoon added that further preclinical and clinical studies are being carried out, in collaboration with institutions such as the University of Ruhuna and the Faculty of Indigenous Medicine, University of Colombo.
Furthermore, he said that plans are underway to partner with international research centres to validate the product’s effectiveness and expand its recognition globally.
He stressed that the long-term goal is to establish the nutraceutical as an internationally recognised cancer-fighting product, while contributing significantly to the country’s economy through exports.